{
 "awd_id": "1113085",
 "agcy_id": "NSF",
 "tran_type": "Grant",
 "awd_istr_txt": "Standard Grant",
 "awd_titl_txt": "SBIR Phase I:  Development of Novel Dendrimer-based Technologies for Phosphorylation Analyses",
 "cfda_num": "47.084",
 "org_code": "15030000",
 "po_phone": "7032922160",
 "po_email": "rshuman@nsf.gov",
 "po_sign_block_name": "Ruth Shuman",
 "awd_eff_date": "2011-07-01",
 "awd_exp_date": "2011-12-31",
 "tot_intn_awd_amt": 150000.0,
 "awd_amount": 150000.0,
 "awd_min_amd_letter_date": "2011-06-07",
 "awd_max_amd_letter_date": "2011-06-07",
 "awd_abstract_narration": "This Small Business Innovation Research (SBIR) Phase I project addresses the unmet needs for effective analysis of protein phosphorylation, a process where a phosphate group is added to a protein to change its function. Protein phosphorylation is a crucial modification of proteins; its abnormalities have been implicated in many diseases. Therefore, assessing the phosphorylation status of individual proteins or classes of proteins, qualitatively or quantitatively, has become a routine but extremely important step in the majority of life science research labs. Existing technologies have glaring deficiencies, including low reproducibility, poor recovery, high cost, reduced selectivity and prolonged experiment time. The platform technology to be developed during this Phase I project will greatly alleviate these shortcomings by providing lucrative, general approaches for phosphorylation analyses. The technologies will enable general phosphorylation detection, cost-effective inhibitor screenings, kinase/phosphatase activity quantitation, and efficient phosphopeptide enrichment for proteomic experiments.\r\n\r\nThe broader/commercial impacts of this research are the development of platform technology to improve a set of biochemical assays, and help the discovery of new therapeutic targets. Protein phosphorylation and kinase inhibitors as drug targets are currently at the peak of research and development (R&D), responsible for over 30% of the total drug discovery expenses. These R&D activities could greatly benefit from the proposed technologies due to their innovative design and versatile features for optimum efficiency and the ability to reproducibly explore phosphorylation events in unprecedented depth. These should provide invaluable tools and address needs of many bioscience research labs/facilities in academic and industrial settings.",
 "awd_arra_amount": 0.0,
 "dir_abbr": "TIP",
 "org_dir_long_name": "Directorate for Technology, Innovation, and Partnerships",
 "div_abbr": "TI",
 "org_div_long_name": "Translational Impacts",
 "awd_agcy_code": "4900",
 "fund_agcy_code": "4900",
 "pi": [
  {
   "pi_role": "Principal Investigator",
   "pi_first_name": "Anton",
   "pi_last_name": "Iliuk",
   "pi_mid_init": "",
   "pi_sufx_name": "",
   "pi_full_name": "Anton Iliuk",
   "pi_email_addr": "anton.iliuk@tymora-analytical.com",
   "nsf_id": "000582480",
   "pi_start_date": "2011-06-07",
   "pi_end_date": null
  }
 ],
 "inst": {
  "inst_name": "Tymora Analytical Operations, LLC",
  "inst_street_address": "1201 CUMBERLAND AVE",
  "inst_street_address_2": "STE 209",
  "inst_city_name": "WEST LAFAYETTE",
  "inst_state_code": "IN",
  "inst_state_name": "Indiana",
  "inst_phone_num": "7654906834",
  "inst_zip_code": "479061359",
  "inst_country_name": "United States",
  "cong_dist_code": "04",
  "st_cong_dist_code": "IN04",
  "org_lgl_bus_name": "TYMORA ANALYTICAL OPERATIONS LLC",
  "org_prnt_uei_num": "",
  "org_uei_num": "ZFFZKDYTF5Q9"
 },
 "perf_inst": {
  "perf_inst_name": "Tymora Analytical Operations, LLC",
  "perf_str_addr": "1201 CUMBERLAND AVE",
  "perf_city_name": "WEST LAFAYETTE",
  "perf_st_code": "IN",
  "perf_st_name": "Indiana",
  "perf_zip_code": "479061359",
  "perf_ctry_code": "US",
  "perf_cong_dist": "04",
  "perf_st_cong_dist": "IN04",
  "perf_ctry_name": "",
  "perf_ctry_flag": "1"
 },
 "pgm_ele": [
  {
   "pgm_ele_code": "537100",
   "pgm_ele_name": "SBIR Phase I"
  }
 ],
 "pgm_ref": [
  {
   "pgm_ref_code": "1491",
   "pgm_ref_txt": "BIOTECH, BIOCHEM & BIOMASS ENG"
  },
  {
   "pgm_ref_code": "5371",
   "pgm_ref_txt": "SMALL BUSINESS PHASE I"
  },
  {
   "pgm_ref_code": "8038",
   "pgm_ref_txt": "Biotechnology"
  },
  {
   "pgm_ref_code": "9184",
   "pgm_ref_txt": "BIOTECHNOLOGY - INFRASTRUCTURE"
  }
 ],
 "app_fund": [
  {
   "app_code": "0111",
   "app_name": "NSF RESEARCH & RELATED ACTIVIT",
   "app_symb_id": "040100",
   "fund_code": "01001112DB",
   "fund_name": "NSF RESEARCH & RELATED ACTIVIT",
   "fund_symb_id": "040100"
  }
 ],
 "oblg_fy": [
  {
   "fund_oblg_fiscal_yr": 2011,
   "fund_oblg_amt": 150000.0
  }
 ],
 "por": {
  "por_cntn": "<div class=\"porColContainerWBG\">\n<div class=\"porContentCol\"><p>This Small Business Innovation Research (SBIR) Phase I project was designed to help address the unmet needs for effective analysis of protein phosphorylation, a process where a phosphate group is added to a protein to change its function. Protein phosphorylation is a crucial modification of proteins; its abnormalities have been implicated in many diseases, most importantly cancer. Therefore, assessing the phosphorylation status of individual proteins or classes of proteins, qualitatively or quantitatively, has become a routine but extremely important step in the majority of life science research labs. Existing technologies have glaring deficiencies, including low reproducibility, poor recovery, high cost, reduced selectivity and prolonged experiment time. The platform technology which was being developed during this Phase I project has the potential greatly alleviate these shortcomings by providing lucrative, general approaches for phosphorylation analyses. The technologies will enable general phosphorylation detection, cost-effective inhibitor screenings, kinase/phosphatase activity quantitation, and efficient phosphopeptide enrichment for proteomic experiments. Overall, the developed technology will improve the discovery and development process of more effective drugs for cancer and other diseases.</p>\n<p>The broader/commercial impacts of this research are the development of platform technology to improve a set of biochemical assays, and help the discovery of new therapeutic targets. Protein phosphorylation and kinase inhibitors as drug targets are currently at the peak of research and development (R&amp;D), responsible for over 30% of the total drug discovery expenses. These R&amp;D activities could greatly benefit from the proposed technologies due to their innovative design and versatile features for optimum efficiency and the ability to reproducibly explore phosphorylation events in unprecedented depth. These should provide invaluable tools and address needs of many bioscience research labs/facilities in academic and industrial settings.</p>\n<p>Over the past 6 months of the Phase I award period, we were able to meet the majority of the proposed objectives by testing and confirming the feasibility of our technological innovations in the submitted applications. We were able to confirm and demonstrate the technologies as significant improvements over existing products not only for biochemical assays in a general laboratory setting, but also as the screening tool for potential cancer drugs.</p>\n<p>&nbsp;</p><br>\n<p>\n\t\t\t\t      \tLast Modified: 02/01/2012<br>\n\t\t\t\t\tModified by: Anton&nbsp;Iliuk</p>\n</div>\n<div class=\"porSideCol\"></div>\n</div>",
  "por_txt_cntn": "\nThis Small Business Innovation Research (SBIR) Phase I project was designed to help address the unmet needs for effective analysis of protein phosphorylation, a process where a phosphate group is added to a protein to change its function. Protein phosphorylation is a crucial modification of proteins; its abnormalities have been implicated in many diseases, most importantly cancer. Therefore, assessing the phosphorylation status of individual proteins or classes of proteins, qualitatively or quantitatively, has become a routine but extremely important step in the majority of life science research labs. Existing technologies have glaring deficiencies, including low reproducibility, poor recovery, high cost, reduced selectivity and prolonged experiment time. The platform technology which was being developed during this Phase I project has the potential greatly alleviate these shortcomings by providing lucrative, general approaches for phosphorylation analyses. The technologies will enable general phosphorylation detection, cost-effective inhibitor screenings, kinase/phosphatase activity quantitation, and efficient phosphopeptide enrichment for proteomic experiments. Overall, the developed technology will improve the discovery and development process of more effective drugs for cancer and other diseases.\n\nThe broader/commercial impacts of this research are the development of platform technology to improve a set of biochemical assays, and help the discovery of new therapeutic targets. Protein phosphorylation and kinase inhibitors as drug targets are currently at the peak of research and development (R&amp;D), responsible for over 30% of the total drug discovery expenses. These R&amp;D activities could greatly benefit from the proposed technologies due to their innovative design and versatile features for optimum efficiency and the ability to reproducibly explore phosphorylation events in unprecedented depth. These should provide invaluable tools and address needs of many bioscience research labs/facilities in academic and industrial settings.\n\nOver the past 6 months of the Phase I award period, we were able to meet the majority of the proposed objectives by testing and confirming the feasibility of our technological innovations in the submitted applications. We were able to confirm and demonstrate the technologies as significant improvements over existing products not only for biochemical assays in a general laboratory setting, but also as the screening tool for potential cancer drugs.\n\n \n\n\t\t\t\t\tLast Modified: 02/01/2012\n\n\t\t\t\t\tSubmitted by: Anton Iliuk"
 }
}